
May 22 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NEW NOVO NORDISK INITIATIVES SUPPORT PATIENT ACCESS TO AUTHENTIC, FDA-APPROVED WEGOVY® AS FEDERAL BAN ON MASS COMPOUNDING OF "SEMAGLUTIDE" TAKES EFFECT
NOVO NORDISK A/S - ONE-TIME $199 FIRST-MONTH OFFER FOR WEGOVY THROUGH JUNE 30, 2025
NOVO NORDISK A/S - SELF-PAYING PATIENTS OFFERED FIRST MONTH OF WEGOVY FOR $199
NOVO NORDISK: FOR SUBSEQUENT MONTHS, SELF-PAY PATIENTS WILL PAY $499 PER MONTH
Further company coverage: [NOVOb.CO]